kallikrein

(redirected from Plasma kallikrein)
Also found in: Dictionary.

kallikrein

 [kal″ĭ-kre´in]
any of several serine endopeptidases that cleave kininogens to form kinins.
plasma kallikrein a hydrolytic enzyme of the plasma that cleaves HMW (high-molecular-weight) kininogen to produce bradykinin. It also activates several blood coagulation factors and plasminogen. It is formed from prekallikrein by activated coagulation factor XII.
tissue kallikrein a hydrolytic enzyme that cleaves LMW kininogen to produce kallidin. It and closely related forms are found in tissues and various glandular secretions such as lymph, pancreatic juice, urine, and saliva.

kal·li·kre·in

(kal'i-krē'in),
A group of enzymes (for example, plasma, tissue, pancreatic, urinary, or submandibular kallikrein) that converts kininogen by proteolysis to bradykinin or kallidin. Trypsin and plasmin can also effect the conversion. Plasma kallikrein activates factor XII and acts on kininogen. Tissue kallikrein is a serine endopeptidase that can generate kallidin from kininogen.

kallikrein

/kal·li·kre·in/ (kal″ĭ-kre´in) any of several serine proteinases that cleave kininogens to form kinins.
plasma kallikrein  a plasma hydrolase that cleaves HMW kininogen to produce bradykinin and also activates blood coagulation factors XII and VII and plasminogen.
tissue kallikrein  a hydrolase of tissues and various glandular secretions that cleaves LMW kininogen to form kallidin.

KLK4

A gene on chromosome 19q13.41 that encodes a serine protease expressed in the prostate.

Molecular pathology
Mutations of KLK4 cause amelogenesis imperfecta hypomaturation type 2A1.

kal·li·kre·in

(kal'i-krē'in)
A group of enzymes (e.g., plasma, tissue, pancreatic, urinary, submandibular kallikrein) that can convert kininogen by proteolysis to bradykinin or kallidin; trypsin and plasmin can also effect the conversion; plasma kallikrein activates the Hageman factor and acts on kininogen. Tissue kallikrein is a serine endopeptidase that can generate kallidin from kininogen.
Synonym(s): kininogenase, kininogenin.

Kallikrein

Any of a group of compounds in the body known as serine endopeptidases that help to break down proteins into smaller units. Prostate-specific antigen belongs to this group of chemicals. A recently discovered kallikrein may be useful as a biomarker for ovarian cancer.
Mentioned in: Ovarian Cancer

kal·li·kre·in

(kal'i-krē'in)
A group of enzymes that can convert kininogen by proteolysis to bradykinin or kallidin.

kallikrein

(kal´ikrē´in),
n a group of enzymes (plasma, tissue, pancreatic, urinary, submandibular kallikrein) that can convert kininogen to bradykinin or kallidin; trypsin and plasmin can also affect the conversion.
kallikrein-kinin system,
n a proposed hormonal system that functions within the kidney, with the en-zyme kallikrein in the re-nal cortex mediating production of bradykinin, which acts as a vasodilator peptide.

kallikrein

any of a group of proteolytic enzymes present in various glands, lymph, urine, blood plasma, etc., or produced directly from mast cells or basophils, or indirectly from activated platelets. The major action of kallikreins is the liberation of kinins from α-2-globulins (kininogens), and they hence have vasodilator and whealing actions.

kallikrein-kinin system
the enzyme system responsible for capillary permeability and smooth muscle contraction.
References in periodicals archive ?
Andrew Crockett, KalVista's CEO, said: "This financing round attracted significant demand from major healthcare investors and we are delighted with this vote of confidence in our strategy to develop best-in-class plasma kallikrein inhibitors in serious diseases.
NASDAQ:DYAX) today announced results from a preclinical study of DX-2930, their internally developed, fully human monoclonal antibody inhibitor of plasma kallikrein, at the 2013 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting which is taking place February 22-26, 2013 in San Antonio, TX.
Work in the Feener lab had previously implicated plasma kallikrein in diabetic eye complications.
Because of the extreme susceptibility of ITIH4 to plasma kallikrein and the partial homology of the amino acid sequence to that of bradykinin released from high-molecular-mass kininogen by plasma kallikrein, human ITIH4 had been proposed to be a potential precursor of bioactive peptides (1, 2).
KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME.
KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries.
BioCryst) announced the selection of two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
KalVista will use the new funding to accelerate the development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME), the leading cause of working-age adult blindness.
In addition, BioCryst has several early-stage programs: BCX4161 and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema, BCX4430, a broad spectrum antiviral for hemorrhagic fevers, and BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C.
Dyax) announced positive results from both preclinical studies of the investigational product DX-2930 and its biomarker assay program for detection of contact system activation of plasma kallikrein (pKal) at American Society of Hematology Annual Meeting and Exposition on December 7-10, 2013.
The Company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need.
In addition, BioCryst is advancing two preclinical programs: BCX5191, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and BCX4161, an oral inhibitor of plasma kallikrein for hereditary angioedema.